Application of mesenchymal stem cell therapy in kidney transplantation: a continued story
10.3969/j.issn.1674-7445.2023228
- VernacularTitle:间充质干细胞疗法在肾移植中的应用：一个未完待续的故事
- Author:
Siyu XIE
1
;
Jun LU
1
Author Information
1. The 900th Hospital of the Joint Logistics Support Force of Chinese People's Liberation Army, Fujian Provincial Key Laboratory of Transplantation Biology, Fuzhou 350025, China.
- Publication Type:ExpertForum
- Keywords:
Mesenchymal stem cell;
Kidney transplantation;
Immunomodulation;
Tissue repair;
Exosome;
Immunosuppressant;
Rejection;
Inflammation
- From:
Organ Transplantation
2024;15(3):398-405
- CountryChina
- Language:Chinese
-
Abstract:
Immunosuppressant is one of the main preventive measures for rejection after organ transplantation, whereas it may reduce the host response capability to pathogens and increase the risk of infection. In recent years, the application of mesenchymal stem cell (MSC) therapy in the field of solid organ transplantation has attracted widespread attention. Preclinical studies have shown that MSC therapy may prolong the survival time of transplant kidney, induce immune tolerance, accelerate the repair of acute kidney injury and promote the recovery of renal function. Clinical trials have confirmed the safety, tolerance and effectiveness of MSC therapy. Consequently, general characteristics, immunomodulation and tissue repair function of MSC, and the application of MSC in clinical trials of kidney transplantation were reviewed, the unresolved issues were briefly discussed and the prospects for subsequent research were predicted, aiming to provide reference for promoting the application of MSC therapy in clinical kidney transplantation.
